Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Harmony Biosciences Holdings Inc (NQ: HRMY ) 33.95 +0.54 (+1.62%) Streaming Delayed Price Updated: 2:52 PM EST, Nov 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Harmony Biosciences Holdings Inc < Previous 1 2 3 4 5 6 7 Next > Why Harmony Biosciences (HRMY) Stock Is Down 18% Today October 30, 2024 Harmony Biosciences shares are trading lower by 17% Wednesday afternoon. The company announced a public offering of up to 8 million common stock shares from selling shareholders. Via Benzinga Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript October 29, 2024 HRMY earnings call for the period ending September 30, 2024. Via The Motley Fool Topics Earnings Exposures Financial Analyst Expectations For Harmony Biosciences's Future October 29, 2024 Via Benzinga Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat October 29, 2024 The company is focused on developing its pipeline of sleep and epilepsy drugs. Via Investor's Business Daily Earnings Outlook For Harmony Biosciences October 28, 2024 Via Benzinga Breaking Down Harmony Biosciences: 6 Analysts Share Their Views October 02, 2024 Via Benzinga Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says September 10, 2024 UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56. UBS highlights Harmony's potential for growth, projecting a 19% CAGR for Wakix sales through 2026. Via Benzinga Unveiling 6 Analyst Insights On Harmony Biosciences September 10, 2024 Via Benzinga Analyst Expectations For Harmony Biosciences's Future August 06, 2024 Via Benzinga A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts June 21, 2024 Via Benzinga Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript August 06, 2024 HRMY earnings call for the period ending June 30, 2024. Via The Motley Fool Topics Earnings Exposures Financial HRMY Stock Earnings: Harmony Biosciences Beats EPS, Beats Revenue for Q2 2024 August 06, 2024 HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028 August 06, 2024 From Harmony Biosciences Via GlobeNewswire 7 Cheap Biotech Stocks With Major Upside Potential July 09, 2024 While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. Via InvestorPlace 7 Undervalued Biotech Stocks to Buy for Big-Time Returns July 01, 2024 The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive. Via InvestorPlace Key Takeaways From Harmony Biosciences Analyst Ratings April 30, 2024 Via Benzinga Evaluating Harmony Biosciences: Insights From 8 Financial Analysts March 28, 2024 Via Benzinga Analyst Ratings For Harmony Biosciences February 22, 2024 Via Benzinga 7 Biotech Stocks to Buy on the Dip: June 2024 June 24, 2024 With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. Via InvestorPlace Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In May 14, 2024 Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. Via Benzinga Topics Cannabis Exposures Cannabis Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript April 30, 2024 HRMY earnings call for the period ending March 31, 2024. Via The Motley Fool Topics Earnings Exposures Financial HRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024 April 30, 2024 HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View April 30, 2024 Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with... Via Benzinga Topics Earnings Exposures Financial Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy April 30, 2024 From Harmony Biosciences Via GlobeNewswire Updates: HRMY, MELI, SWAV February 28, 2024 Another day, another slew of quarterly update reports for our followed stocks. Via Talk Markets Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript February 22, 2024 HRMY earnings call for the period ending December 31, 2023. Via The Motley Fool Topics Earnings Exposures Financial Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates February 22, 2024 From Harmony Biosciences Via GlobeNewswire The 3 Most Undervalued Small-Cap Stocks to Buy in February 2024 February 12, 2024 Small-cap stocks are the first ones to rally on a new business cycle, such as the business cycle starting recently. Via InvestorPlace The 3 Most Undervalued Russell 2000 Stocks to Buy in February 2024 February 07, 2024 Although the high-flying entities still capture Wall Street’s attention, astute investors should look to undervalued Russell 2000 stocks. Via InvestorPlace NASDAQ:HRMY: good value for what you're paying. January 25, 2024 In a market where value is scarce, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) offers a refreshing opportunity with its solid fundamentals. Via Chartmill < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
